Emerging immunotargets in metastatic renal cell carcinoma

John Kucharczyk, Marc R. Matrana, Matteo Santoni, Francesco Massari, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Stefano Cascinu, Rodolfo Montironi, Moch Holger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

Original languageEnglish (US)
Pages (from-to)771-776
Number of pages6
JournalCurrent Drug Targets
Volume17
Issue number7
StatePublished - Jun 1 2016

Fingerprint

Programmed Cell Death 1 Receptor
Renal Cell Carcinoma
Immunotherapy
Interferons
Interleukin-2
Toxicity
Cells
Cytokines
Ligands
Therapeutics
Clinical Trials
Safety
Neoplasms

Keywords

  • Immunotargets
  • Immunotherapy
  • Kidney cancer
  • Metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Kucharczyk, J., Matrana, M. R., Santoni, M., Massari, F., Scarpelli, M., Cheng, L., ... Holger, M. (2016). Emerging immunotargets in metastatic renal cell carcinoma. Current Drug Targets, 17(7), 771-776.

Emerging immunotargets in metastatic renal cell carcinoma. / Kucharczyk, John; Matrana, Marc R.; Santoni, Matteo; Massari, Francesco; Scarpelli, Marina; Cheng, Liang; Lopez-Beltran, Antonio; Cascinu, Stefano; Montironi, Rodolfo; Holger, Moch.

In: Current Drug Targets, Vol. 17, No. 7, 01.06.2016, p. 771-776.

Research output: Contribution to journalArticle

Kucharczyk, J, Matrana, MR, Santoni, M, Massari, F, Scarpelli, M, Cheng, L, Lopez-Beltran, A, Cascinu, S, Montironi, R & Holger, M 2016, 'Emerging immunotargets in metastatic renal cell carcinoma', Current Drug Targets, vol. 17, no. 7, pp. 771-776.
Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L et al. Emerging immunotargets in metastatic renal cell carcinoma. Current Drug Targets. 2016 Jun 1;17(7):771-776.
Kucharczyk, John ; Matrana, Marc R. ; Santoni, Matteo ; Massari, Francesco ; Scarpelli, Marina ; Cheng, Liang ; Lopez-Beltran, Antonio ; Cascinu, Stefano ; Montironi, Rodolfo ; Holger, Moch. / Emerging immunotargets in metastatic renal cell carcinoma. In: Current Drug Targets. 2016 ; Vol. 17, No. 7. pp. 771-776.
@article{ca0f4b5b77044be6ade8e280b15f490e,
title = "Emerging immunotargets in metastatic renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.",
keywords = "Immunotargets, Immunotherapy, Kidney cancer, Metastatic renal cell carcinoma",
author = "John Kucharczyk and Matrana, {Marc R.} and Matteo Santoni and Francesco Massari and Marina Scarpelli and Liang Cheng and Antonio Lopez-Beltran and Stefano Cascinu and Rodolfo Montironi and Moch Holger",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "771--776",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Emerging immunotargets in metastatic renal cell carcinoma

AU - Kucharczyk, John

AU - Matrana, Marc R.

AU - Santoni, Matteo

AU - Massari, Francesco

AU - Scarpelli, Marina

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Cascinu, Stefano

AU - Montironi, Rodolfo

AU - Holger, Moch

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

AB - Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

KW - Immunotargets

KW - Immunotherapy

KW - Kidney cancer

KW - Metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84964297866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964297866&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 771

EP - 776

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 7

ER -